slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,471
Current window 34,801-34,830
Pages 3,950
Rows per page 30
Component
34,801-34,830 of 118,471
294
The slide uses direct quotes from a KOL to undermine the company's narrative of drug efficacy and market adoption.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
300
The slide uses a Q&A format to highlight specific quotes from a trial investigator regarding drug safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
310
The slide uses bolding and highlighting to emphasize negative feedback from a key opinion leader.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
311
The slide uses a Q&A format to document expert testimony regarding trial integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
313
The slide uses a Q&A format to highlight the expert's skepticism about the company's reporting practices.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
319
The slide uses a Q&A transcript format to expose flaws in clinical trial integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
321
The slide uses a Q&A transcript format to expose flaws in the clinical trial design regarding pill size.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
322
The slide uses a Q&A transcript format to undermine the company's product value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
323
The slide uses a combination of summary text and direct interview transcripts to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
326
The slide uses Q&A transcripts to expose the risks of the drug and the burden of monitoring.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
330
Includes direct Q&A transcripts from a trial investigator/endocrinologist.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
331
The slide uses direct quotes from an endocrinologist/KOL to undermine the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
333
The slide uses direct quotes from a trial investigator to undermine the company's value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
335
The slide uses direct quotes from an interview to highlight the discrepancy between public promotion and private clinical reality.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
351
The slide uses direct quotes to highlight physician skepticism and lack of awareness regarding the drug's trial flaws.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
353
The slide uses a Q&A format to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
355
The slide uses a Q&A format to build a case for market substitution risk.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
356
The slide uses a Q&A transcript format to highlight low adoption rates and physician skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
357
The slide uses a 'villain' narrative by framing a specific researcher (Jennifer Miller) and patient families as a 'cult' driving artificial demand.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
361
The slide uses direct quotes from a pediatric endocrinologist to undermine the viability of a drug (Vykat/diazoxide).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
365
The slide uses direct quotes from an endocrinologist to undermine the product's differentiation and pricing justification.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
368
The slide highlights the physician's skepticism and the administrative hurdles faced with the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
371
The slide uses a Q&A transcript format to expose potential conflicts of interest between a company (Soleno) and a patient association.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
380
The slide uses direct quotes to expose the contradiction between the physician's knowledge of drug inefficacy and their continued prescription behavior.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
381
The slide uses direct quotes from an expert consultation to contrast grassroots patient enthusiasm with professional indifference.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
382
The slide uses a Q&A transcript format to highlight the physician's frustration and lack of guidance from the manufacturer.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
388
The slide uses a combination of summary text and direct interview transcripts to build a case against the drug's adoption.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
392
The slide uses direct quotes and Q&A excerpts to build a case against the safety of the drug Vykat in the context of PWS treatment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
394
The slide uses expert interview transcripts to undermine the value proposition of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
407
The slide presents a summary of an expert interview, highlighting the endocrinologist's preference for GLP-1s over Vykat for PWS patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits